Joshua K. Sabari, MD, discusses the need for EGFR inhibitors designed specifically to treat patients with EGFR-mutant non–small cell lung cancer and an exon 20 insertion.
Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Grossman School of Medicine, discusses the need for EGFR inhibitors designed specifically to treat patients with EGFR-mutant non–small cell lung cancer (NSCLC) and an exon 20 insertion.
The standard of care for patients with EGFR-mutant disease is chemotherapy combination therapy which has been shown to achieve a median survival of about 7 months. According to Sabari, the survival rate reveals a need for more effective treatment overall.
The landscape for those with an exon 20 insertion is less populated with effective agents, says Sabari. These patients do not respond to treatment with traditional tyrosine kinase inhibitors like those with exon 19 and 21 insertions tend to respond. More exon 20-specific inhibitor are needed in the space. Further, there is a need for therapies with better safety profiles for patients with EGFR-mutant and exon 20 insertion-positive NSCLC.
Selection of First-Line NSCLC Therapy Influenced by Delayed Testing
March 8th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.
Read More
Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment
February 19th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, held a discussion on the use of biomarker testing in patients with advanced non–small cell lung cancer. This is the first of 2 articles based on this event.
Read More